Analysis of serum cancer procoagulant activity and its possible use as a tumor marker.

Abstract

The two objectives of the study were to determine whether a procedure could be developed for measuring cancer procoagulant (CP) activity in human serum and if this procedure provided a method for distinguishing people with cancer from those without cancer. A procedure was developed for processing human serum such that the activity of other coagulation enzymes would be minimized and the activity of cancer procoagulant could be measured. In a blinded study, we collected serum from 61 individuals in serum separator tubes, removed the clot by centrifugation, extracted the serum with a simple, single step procedure and analyzed the extract for CP activity. The results indicate that this test could correctly identify about 92% of the cancer patient serum samples and about 75% of the non-cancer patients serum samples, for an overall accuracy of about 85%.

• Authors: S G Gordon, B Benson
• Journal: Thrombosis research (Thromb Res) Vol. 56 Issue 3 Pg. 431-40 (Nov 01 1989) ISSN: 0049-3848 [Print] United States
• PMID: 2617480 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• Blood Coagulation Factors
• Neoplasm Proteins
• Cysteine Endopeptidases
• cancer procoagulant

Topics

• Biomarkers, Tumor (blood)
• Blood Coagulation Factors (analysis)
• Blood Coagulation Tests
• Cysteine Endopeptidases (blood)
• Factor VII Deficiency (blood)
• Female
• Humans
• Male
• Neoplasm Proteins (blood)
• Neoplasms (blood, diagnosis, enzymology)
• Predictive Value of Tests